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Background. To evaluate the association of migraine and asthma and to estimate the risk of hypertensive disorders of pregnancy
in relation to maternal comorbid migraine and asthma. Methods.R e p r o d u c t i v ea g ew o m e n( N = 3.731) were interviewed
during early pregnancy. At the time of interview, we ascertained participants’ migraine and asthma status. From medical
records, we collected information to allow the diagnosis of pregnancy-induced hypertension (PIH) and preeclampsia. Odds
ratios (ORs) and 95% conﬁdence intervals (CIs) were estimated using logistic regression procedures. Results. After adjusting for
confounders, migraineurs had 1.38-fold increased odds of asthma as compared with nonmigraineurs (95% CI 1.09–1.38). The
odds of hypertensive disorders of pregnancy were highest among women with comorbid migraine-asthma. The ORs for PIH
preeclampsia and the two disorders combined were 2.53 (95% CI 1.39–4.61), 3.53 (95% CI 1.51–8.24), and 2.64 (95% CI 1.56–
4.47), respectively, for women with comorbid migraine-asthma as compared with those who had neither disorder. Conclusion.
These ﬁndings conﬁrm prior reports and extend the literature by documenting particularly high odds of pregnancy-induced
hypertension and preeclampsia among women with comorbid migraine-asthma. Increased knowledge about the prevalence and
sequelae of comorbidities during pregnancy may lead to improved symptom management and perinatal outcomes.
1.Introduction
Migraine, a recurrent neurovascular headache disorder, is
characterized by episodes of severe throbbing, pulsatile
headache associated with nausea, vomiting, photophobia,
phonophobia, and aversion to physical activity [1, 2]. The
prevalence of migraine rises from 4% before puberty to a
peak of 25% in women during their childbearing years, with
a decrease after menopause [3]. An estimated 35 million
US adults (18% of women and 6% of men) are thought to
suﬀer from migraine [4]. Asthma, an inﬂammatory disease
of the lower respiratory tract manifests as intermittent
constriction of the bronchial airways [5]. Asthma attacks
can cause a multitude of symptoms ranging in severity from
mild to life-threatening. These symptoms include wheezing,
breathlessness,chesttightness,andcoughing.Approximately
8% of the US population reported that they currently have
asthma [6]. Both conditions are known to negatively aﬀect
the overall quality of life by limiting physical activity [7, 8],
and adversely impacting sleep [9]. Most population-based
[10,11]andclinical[12,13],butnotall[14,15],studieshave
documented associations between migraine and asthma. As
early as 1977, some investigators elected to describe asthma
as “pulmonary migraine”[ 16]o r“ acephalgic migraine”[ 17].
Both migraine and asthma are prevalent among preg-
nant women; both conditions are known to be associated
with adverse pregnancy outcomes [18–22]. For example,
investigators have reported increased risks of preeclampsia
among migraineurs [20, 22–24], and others have noted
increased risk of the condition among asthmatics [25–27].
The high prevalence of migraine and asthma together with
the potential for cooccurrence of these disorders is a concern
because a diagnosis of one should lead to increased vigilance
for screening and treating the other. There are, however,2 Journal of Pregnancy
no published reports on the cooccurrence of migraine and
asthma among pregnant women. We, therefore, examined
the relationship between migraine and asthma in a well-
characterized cohort of pregnant women who were inter-
viewed during early pregnancy. We also investigated the
association of comorbid migraine-asthma with the incidence
of pregnancy-induced hypertension and preeclampsia. We
hypothesize that women with comorbid migraine-asthma
would have the highest risk of these hypertensive disorders
of pregnancy.
2. Methods
2.1. Study Design and Setting. We analyzed data from
the Omega Study, a prospective cohort study designed
to examine risk factors of adverse pregnancy outcomes
including preeclampsia. Participants were recruited from
women attending prenatal care clinics aﬃliated with Swedish
Medical Center and Tacoma General Hospital in Seattle and
Tacoma, WA, USA. Recruitment began in December 1996
[28]. The study protocol was approved by the Institutional
Review Boards of Swedish Medical Center and Tacoma Gen-
eral Hospital. All participants provided informed consent.
Eligible women were those who began prenatal care
before 20 weeks of gestation, spoke and read English, were
≥18 years of age, and planned to carry the pregnancy to
term and deliver at either of the two hospitals. During early
pregnancy, participants were asked to complete a structured
interviewer administered questionnaire regarding sociode-
mographic characteristics, lifestyle habits, and medical and
reproductive histories. Pregnancy outcome information was
abstracted from hospital and clinic medical records.
2.2. Analytical Population. T h ea n a l y t i c a ls t u d yp o p u l a t i o n
was derived from participants enrolled in the Omega Study
between 1996 and 2008. During this period, 5,063 eligible
women were approached and 4,000 (approximately 79%)
agreed to participate. Women with incomplete information
concerning prior history of migraine (n = 267) or asthma
diagnosis (n = 2) were excluded from this analysis. A cohort
of 3,731 women remained for analysis.
2.3. Data Collection. From structured questionnaire and
medical records, we obtained information of covari-
ates including maternal age, educational attainment, self-
reported height, pre-pregnancy weight, reproductive and
medical histories, and medical histories of ﬁrst-degree
family members. We also collected information on maternal
smoking during pregnancy. Pre-pregnancy body mass index
(BMI) was calculated as pre-pregnancy weight in kilograms
divided by height in meters squared. Maternal history of
migraine diagnosis was determined by response to the
question “ H a sad o c t o re v e rt o l dy o ut h a ty o uh a v em i g r a i n e
headache?” Similarly, maternal history of asthma diagnosis
was determined by response to the question “Has a doctor
ever told you that you have asthma?”
Maternal medical records were reviewed to collect
detailed medical and clinical information. The diagnosis
of pregnancy-induced hypertension (PIH) and preeclamp-
sia (PE) was made using abstracted medical record data
according to American College of Obstetricians and Gyne-
cologists (ACOG) guidelines [29]. These guidelines deﬁned
preeclampsia as new onset hypertension with proteinuria
in women who are beyond 20 weeks of gestation. Hyper-
tension was deﬁned as sustained blood pressure readings
of ≥140/90mmHg taken ≥6 hours apart. Proteinuria was
deﬁned as urine protein concentrations of 30mg/dL on
t w oo rm o r er a n d o ms p e c i m e n sc o l l e c t e da tl e a s t4h o u r s
apart. Hereinafter, the term “pregnancy-induced hyper-
tension (PIH)” is used to describe those women with
hypertension without proteinuria. The term “preeclampsia”
is used to describe those women with both pregnancy-
induced hypertension and proteinuria.
2.4. Statistical Analyses. We compared the frequency dis-
tribution of sociodemographic, lifestyle, behavioral and
medical history characteristics of participants according to
whether or not they had received a physician diagnosis of
migraine prior to the index pregnancy. We used unadjusted
and multivariable-adjusted logistic regression models to cal-
culate odds ratios (ORs) and 95% conﬁdence intervals (CIs)
of the association between migraine and asthma diagnosis.
We also estimated unadjusted and multivariable adjusted
oddsratiosand95%conﬁdenceintervalstoevaluatethejoint
eﬀect/comorbid eﬀect of migraine and asthma history on
risk of hypertensive disorders in the index pregnancy. For
these analyses, we classiﬁed women by the joint distribution
of prior history of migraine diagnosis (no versus yes) and
priorhistoryofasthma(noversusyes).Thejointdistribution
of the two disorders resulted in the following four categories:
nomigraineandnoasthma;historyofmigraineonly;history
of asthma only; comorbid migraine and asthma. Rothman
and Greenland [30] have previously described this analytical
approach. Polynomial logistic regression procedure was used
to derive OR estimates for the ordinal outcomes (PIH
and preeclampsia). We assessed confounding by entering
covariates into the logistic regression model one at a time
and adjusted ORs were compared to unadjusted ORs.
Final logistic regression models included covariates that
altered unadjusted ORs by 10%, as well as maternal age,
race/ethnicity, parity, marital status, cigarette smoking dur-
ing pregnancy, history of chronic hypertension or diabetes,
pre-pregnancy body mass index, and multifetal pregnancy.
We repeated analyses after excluding gravidas with prior
histories of chronic hypertension or gestational diabetes, as
well as those with multifetal pregnancies. Findings from
these sensitivity analyses were largely similar to results from
our primary analyses. We present continuous variables as
mean with standard deviation. All reported P values are 2-
tailed with statistical signiﬁcance set at 0.05.
3. Results
The sociodemographic, medical, and behavioral charac-
teristics of study participants are summarized in Table 1.
Approximately 18% of women in this cohort reported aJournal of Pregnancy 3
Table 1: Sociodemographic and other characteristics of the cohort, Seattle and Tacoma, WA, USA, 1996–2008.
Entire Cohort Physician-Diagnosed Migraine
Characteristics (N = 3,731) Yes (N = 670) No (N = 3,061) P Value
%% %
Maternal age (years) 32.6 ±4.5
∗ 32.5 ±4.63 2 .7 ±4.50 . 2 7
<20 0.6 0.5 0.6
20–29 22.2 25.8 21.4
30–34 43.6 40.6 44.3 0.14
35–39 27.0 26.3 27.1
≥40 6.6 6.9 6.5
Maternal race/ethnicity
Non-Hispanic white 86.4 88.7 85.9
African American 1.9 1.8 1.9 0.15
Other 11.7 9.5 12.2
Annual household income ($)
<30,000 3.4 3.0 3.5
30,000–69,999 19.8 20.8 19.6 0.79
≥70,000 73.4 72.7 73.6
Missing 3.3 3.6 3.3
Nulliparous 62.5 58.2 63.4 0.01
Education ≤ high school 4.1 4.6 3.9 0.40
Unmarried 9.0 10.5 8.7 0.14
History of diabetes mellitus 1.3 1.3 1.3 0.89
History of chronic hypertension 4.7 8.2 4.0 <0.001
Family history of diabetes mellitus 14.7 16.4 14.4 0.18
Family history of hypertension 50.0 53.1 49.3 0.07
Not employed during pregnancy 18.6 17.6 18.8 0.49
Smoked during pregnancy 5.8 6.1 5.7 0.71
No prenatal vitamin use 2.7 2.8 2.7 0.78
No exercise during pregnancy 13.1 12.5 13.2 0.66
Pre-pregnancy body mass index (kg/m2)2 3 .6 ±5.0
∗ 24.5 ±6.12 3 .4 ±4.7 <0.001
<18.5 4.3 3.9 4.3
18.5–24.9 70.3 67.0 71.0 0.003
25–29.9 16.4 16.4 16.4
≥30 9.0 12.7 8.2
Multiple births 3.2 2.5 3.3 0.29
Gestational age at delivery (weeks) 38.4 ±3.5
∗ 38.3 ±3.43 8 .4 ±3.50 . 5 4
Infant birth weight (gram) 3408 ±604
∗ 3406 ±589 3409 ±608 0.90
∗Mean ± standard deviation (SD).
history of migraine. Migraineurs and nonmigraineurs were
similar with regards to maternal age, race/ethnicity, educa-
tional attainment, marital and smoking status. Migraineurs
were less likely to be nulliparous and were more likely to
have a family and personal history of chronic hypertension,
as compared with nonmigraineurs. Moreover, migraineurs
were more likely to be obese than nonmigraineurs.
The overall prevalence of asthma in this cohort was
13.1%. As shown in Table 2, migraineurs had a 1.44-fold
increased odds of asthma as compared with nonmigraineurs
(unadjusted OR = 1.44; 95% CI 1.14–1.81). After adjusting
for maternal age, parity, marital status, history of chronic
hypertension, and pre-pregnancy body mass index, the
odds ratio was slightly attenuated, though the association
remained statistically signiﬁcant (adjusted OR = 1.38; 95%
CI 1.09–1.74).
We next evaluated the risk of PIH, preeclampsia, and
the two disorders combined (any hypertensive disorder of
pregnancy) in relation to maternal migraine only, asthma
only, and comorbid migraine-asthma status (Table 3). After
adjusting for maternal age, race/ethnicity, parity, marital
status, cigarette smoking, history of chronic hypertension
and pre-pregnancy body mass index, women with comor-
bid migraine-asthma had a 2.53-fold increased odds of
pregnancy-induced hypertension (95% CI 1.39–4.61) as
compared with those women with no history of migraine
or asthma (i.e., the reference group). Further adjustment for
multifetal pregnancies did not materially alter the observed4 Journal of Pregnancy
Table 2:Unadjustedandadjustedoddsratios(ORs)and95%conﬁdenceintervalsofasthmaandmigrainecomorbidity,SeattleandTacoma,
WA, USA, 1996–2008.
Physician-Diagnosed Migraine
Yes (N = 670) No (N = 3,061) Unadjusted OR (95% CI) ∗Adjusted OR (95% CI)
n (%) n (%)
Physician-diagnosed asthma
No 558 (83.3) 2686 (87.7) 1.00 (reference) 1.00 (reference)
Yes 112 (16.7) 375 (12.3) 1.44 (1.14–1.81) 1.38 (1.09–1.74)
∗Adjusted for maternal age, parity, marital status, history of chronic hypertension, and pre-pregnancy body mass index.
Table 3: Unadjusted and adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs) of hypertensive disorders of pregnancy in relation
to maternal migraine and asthma status, Seattle and Tacoma, WA, USA, 1996–2008.
Outcomes No migraine/no asthma Migraine only Asthma only Comorbid Migraine-Asthma
Pregnancy-induced hypertension (PIH)
No, n 2404 479 326 82
Yes, n 167 56 27 17
Unadjusted OR (95% CI) 1.00 (reference) 1.68 (1.22–2.31) 1.19 (0.78–1.82) 2.98 (1.73–5.15)
1Adjusted OR (95% CI) 1.00 (reference) 1.20 (0.84–1.71) 1.04 (0.66–1.63) 2.53 (1.39–4.61)
2Adjusted OR (95% CI) 1.00 (reference) 1.21 (0.85–1.74) 1.03 (0.66–1.62) 2.55 (1.40–4.63)
Preeclampsia (PE)
No, n 2404 479 326 82
Yes, n 72 19 20 8
Unadjusted OR (95% CI) 1.00 (reference) 1.32 (0.79–2.22) 2.05 (1.23–3.41) 3.26 (1.52–6.99)
1Adjusted OR (95% CI) 1.00 (reference) 0.83 (0.46–1.50) 1.89 (1.08–3.28) 3.53 (1.51–8.24)
2Adjusted OR (95% CI) 1.00 (reference) 0.89 (0.49–1.63) 2.00 (1.14–3.49) 3.77 (1.61–8.82)
PIH or PE
No, n 2404 479 326 82
Yes, n 239 75 47 25
Unadjusted OR (95% CI) 1.00 (reference) 1.58 (1.19–2.08) 1.45 (1.04–2.02) 3.07 (1.92–4.89)
1Adjusted OR (95% CI) 1.00 (reference) 1.13 (0.82–1.55) 1.27 (0.88–1.83) 2.64 (1.56–4.47)
2Adjusted OR (95% CI) 1.00 (reference) 1.15 (0.84–1.59) 1.28 (0.88–1.84) 2.69 (1.59–4.56)
Note: Subjects with unknown hypertensive disorder status were excluded from this analysis.
1Adjusted for maternal age, race/ethnicity, parity, marital status, cigarette smoking status, history of chronic hypertension, and pre-pregnancy body mass
index.
2Adjusted for maternal age, race/ethnicity, parity, marital status, cigarette smoking status, history of chronic hypertension, pre-pregnancy body mass index,
and multifetal pregnancy.
association (adjusted OR = 2.55; 95% CI 1.40–4.63). There
was no clear evidence of associations of isolated migraine
(adjusted OR=1.20; 95% CI 0.84–1.71) or asthma only
(adjusted OR = 1.04; 95% CI 0.66–1.63) with the occurrence
of pregnancy-induced hypertension.
Women with a history of asthma only had a 1.89-
fold increased odds of preeclampsia as compared with the
referent group (95% CI 1.08–3.28). No similar association
was observed for women with the diagnosis of migraine
only (adjusted OR=0.83; 95% CI 0.46–1.50). Comorbid
migraine-asthma was associated with a 3.53-fold increased
odds of preeclampsia (adjusted OR = 3.53; 95% CI 1.51–
8.24). Similar patterns of associations were observed when
pregnancy-induced hypertension and preeclampsia were
combined and evaluated as any hypertensive pregnancy
disorder. We repeated the analysis summarized in Table 3
after excluding participants with multifetal pregnancy and
prior histories of chronic hypertension and diabetes. Results
from these sensitivity analyses are included in Table 4.F o r
example, when we assessed the occurrence of hypertensive
disorders of pregnancy among women with no history of
pregestationaldiabetes,theproportionswere0.09,0.13,0.13,
and 0.23 for those with no migraine and no asthma, those
with a history of migraine only, those with a history of
asthma only, and those comorbid migraine and asthma,
respectively. Overall, results from our sensitivity analyses are
similar to those results reported in Table 3.
4. Discussion
Women with a history of migraine had statistically sig-
niﬁcantly higher odds of asthma when compared with
nonmigraineurs (adjusted OR = 1.38; 95% CI 1.09–1.38).
Additionally,theoddsofhypertensivedisordersofpregnancy
were found to be highest among women with comorbidJournal of Pregnancy 5
Table 4: Unadjusted and adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs) of hypertensive disorders of pregnancy in relation
to maternal migraine and asthma status, Seattle and Tacoma, WA, USA, 1996–2008.
No Migraine/No Asthma Migraine Only Asthma Only Comorbid Migraine-Asthma
Pregnancy-induced hypertension (PIH)
No, n 2267 448 308 78
Yes, n 126 35 18 13
Unadjusted OR (95% CI) 1.00 (reference) 1.41 (0.95–2.07) 1.05 (0.63–1.75) 3.00 (1.62–5.54)
1Adjusted OR (95% CI) 1.00 (reference) 1.21 (0.81–1.81) 0.98 (0.58–1.65) 2.44 (1.27–4.69)
Preeclampsia (PE)
No, n 2267 448 308 78
Yes, n 42 7 11 6
Unadjusted OR (95% CI) 1.00 (reference) 0.84 (0.38–1.89) 1.93 (0.98–3.78) 4.15 (1.71–10.06)
1Adjusted OR (95% CI) 1.00 (reference) 0.70 (0.30–1.63) 1.82 (0.91–3.61) 4.11 (1.65–10.19)
PIH or PE
No, n 2267 448 308 78
Yes, n 168 42 29 19
Unadjusted OR (95% CI) 1.00 (reference) 1.27 (0.89–1.80) 1.27 (0.84–1.92) 3.29 (1.94–5.56)
1Adjusted OR (95% CI) 1.00 (reference) 1.11 (0.77–1.60) 1.19 (0.78–1.82) 2.69 (1.53–4.74)
Note: Subjects with history of chronic hypertension or preexisting diabetes mellitus or multifetal pregnancy were excluded from this analysis.
1Adjusted for maternal age, race/ethnicity, parity, marital status, cigarette smoking status, and pre-pregnancy body mass.
migraine-asthma. The ORs for PIH and preeclampsia and
the two disorders combined were 2.53 (95% CI 1.39–
4.61), 3.53 (95% CI 1.51–8.24), and 2.64 (95% CI 1.56–
4.47), respectively, for women with comorbid migraine-
asthma when compared with those women who had neither
disorder. To the best of our knowledge, this is the ﬁrst study
examining the relationship between migraine and asthma in
pregnant women. Although there are no published ﬁndings
forthisrelationshipspeciﬁctopregnantwoman,ourﬁndings
are consistent with population-based [10, 11] and clinic
or hospital-based [12, 13] cross-sectional studies reporting
associations of migraine, headache, and asthma.
Aamodt et al. [31] reported a positive association of both
migraine and other nonmigrainous headache with asthma
among 51,383 Norwegian participants of the Head-HUNT
study. After adjusting for confounding by age, gender, educa-
tion,andsmoking,theauthorsnotedthattheoddsofasthma
was increased 1.5-fold (adjusted OR = 1.5; 95% CI 1.3–
1.7) among migraineurs, as compared with nonmigraineurs.
Non-migrainous headache was also associated with a 1.5-
fold increased risk of asthma in this population (adjusted
OR = 1.5; 95% CI 1.3–1.6). In a case-control study of 64,678
pairs of migraineurs and nonmigraineurs patients, matched
on general practice, gender, and age, Davey et al. [13]
observed increased relative risk of asthma (RR = 1.59; 95%
CI1.54–1.65)amongmigraineurs.Similarly,Lateefetal.[11]
in their recent study of 10,198 children (age 4–18 years),
who participated in the National Health and Nutrition
Examination Surveys (NHANES), reported that children
with headaches had a 1.7-fold increased odds of asthma (OR
= 1.67; 95% CI 1.35–2.06) as compared with those children
without headache individuals with headache as compared to
thosewithout.VonBehrenetal.[32]alsoidentiﬁedapositive
association between self-reported lifetime prevalence of
migraine and asthma. Using data from the 1998 California
Behavioral Risk Factor Surveillance System (BRFSS), the
authors noted that the lifetime prevalence of asthma was
13.9%. They also reported that women with a history of
migrainehadhigheroddsofalifetimehistoryofasthmathan
those without a history of migraine (prevalence ratio (PR) =
1.58; 95% CI 1.26–2.00). No such association was observed
among men (PR = 1.12; 95% CI 0.69–1.82).
The pathogenesis for comorbid migraine and asthma
remains unknown. However, investigators have speculated
that migraine may share some common etiologic factors
(e.g., genetic, biochemical, or environmental factors) with
asthma and that a causal relationship exists between the two
disorders [33, 34]. For example, alterations in inﬂamma-
tory and vasoactive mediators including complement and
immunoglobulins, histamine, cytokines, and nitric oxide
or derangements in arachidonic acid metabolism [35]m a y
underlie the development of migraine and other headaches
among asthmatics [34, 36–38]. Investigators have postulated
that histamine may be an important trigger of a cascade
of neurogenic events that may lead to migraine or other
primary headache disorders by means of CNS vasodilation
or by stimulation of sensory nerve ﬁbers [34]. Alternatively,
migraine and headache disorders may be a secondary mani-
festation of allergies, or a sequelae of its treatment [34]. For
instance, use of beta-blockers, salicylates, and nonsteroidal
anti-inﬂammatorymedicationstotreatmigrainemaytrigger
asthma [35, 39] in some patients. Longitudinal studies are
needed to clarify the temporal relation of the symptoms and
diagnoses of each disorder and to empirically evaluate these
intriguing mechanistic hypotheses.
Migraine and asthma are prevalent medical conditions
among reproductive aged women, and both conditions are
knowntobeassociatedwithadverseperinataloutcomes[18–
22]. Marcoux and colleagues, in their case-control study of
Canadian women [40], noted that those with a history of6 Journal of Pregnancy
migraines had a 2.4-fold increased risk of preeclampsia as
compared with those who did not have migraines (OR =
2.4; 95% CI 1.4–4.2). Adeney et al. [22] in their case-control
study of American women residing in the Paciﬁc Northwest
region of the US reported a positive association between
migraine history and preeclampsia risk. The authors noted
that women with a history of physician-diagnosed migraine
had a 1.8-fold (OR = 1.8; 95% CI, 1.1–2.7) increased risk
of preeclampsia compared with women not having such a
medical history. Similarly, Sanchez et al. [23] in their case-
control study of Peruvian women reported that migraineurs
had a 4.0-fold increased risk of preeclampsia (OR = 4.0; 95%
CI 1.9–8.2) compared with nonmigraineurs. Additionally,
Facchinetti et al. [24] in their prospective cohort study
702 normotensive Italian women with singleton pregnancies
reported that migraine, classiﬁed using the International
Headache Society diagnostic criteria, was associated with
incident hypertensive disorders in pregnancy (OR = 2.85;
95% CI 1.40–5.81).
A substantial literature also suggests increased risks
of hypertensive disorders of pregnancy among pregnant
asthmatics [19, 25–27]. Liu et al. [26] in their retrospective
study of 2,193 Canadian mothers with asthma and 8772
nonasthmatic mother noted preeclampsia risks among asth-
matics (unadjusted OR = 1.80; 95% CI 1.36–2.39). Similar
associations were reported by Demissie and colleagues (25)
who noted that asthmatics in New Jersey had a 2.18-
fold increased risk of preeclampsia as compared with non-
asthmatics (OR = 2.18; 95% CI 1.68–2.83). In 2006, Rudra
et al. [27] in a case-control study of 286 preeclampsia cases
and470normotensivecontrolsinSeattle,WA,USA,reported
that women experiencing asthma symptoms during preg-
nancy were more likely than pregnant nonasthmatics to have
preeclampsia (OR = 2.20; 95% CI 0.79–6.10), and that those
withlong-termpre-pregnancyasthmaandsymptomsduring
pregnancy were at particularly increased preeclampsia risk
(OR = 9.09; 95% CI 1.02–81.6). Collectively, these studies
and those from our present study suggest that pregnant
women with migraine and/or asthma are high-risk patients
that may beneﬁt from particular attention paid to the
management of these disorders during pregnancy [19, 21].
Several limitations of our study merit discussion and
consideration. First, maternal migraine and asthma status
was based on self-reports made during interviews and on
medical records review. Although the questions we used to
ascertain maternal migraine and asthma status have been
widely used in National Health and Nutrition Examina-
tion Surveys (NHANES) and other large epidemiological
studies, [11, 32] and investigators have documented good
agreement between chronic disease classiﬁcation based on
self-reports with information derived from medical records
review [41], we cannot exclude the possibility of that
migraine and asthma status was underreported in our study.
Studies that systematically use screening and conﬁrmatory
diagnostic evaluations will attenuate greatly concerns about
misclassiﬁcation of maternal migraine and asthma diagnoses
in epidemiological studies. Second, although we adjusted
for several potential confounders, we cannot exclude the
possibility of residual confounding due to misclassiﬁcation
of adjusted variables (e.g., maternal pre-pregnancy body
mass index) or confounding by other unmeasured variables
(e.g., the severity and frequency of emergency asthmatic
episodes and medications used during pregnancy). Lastly,
the generalizability of our study may also be limited as
our cohort was primarily comprised of non-Hispanic White
and well-educated women. The concordance of our results
with those from other studies that have included racially,
ethnically, and geographically diverse populations, however,
serves to attenuate these concerns.
In summary, we found associations of migraine and
asthma in a cohort of pregnant women. This observed
comorbidity was associated with markedly elevated odds
of pregnancy-induced hypertension and preeclampsia. If
conﬁrmed in other pregnancy cohorts, observed comorbid-
ity of migraine and asthma along with observed odds of
adverse pregnancy outcomes among gravidas with comorbid
migraine-asthmashouldfurthermotivateincreasedvigilance
in clinical evaluation and management of obstetric patients
withthesedisorders[19,21].Additionally,futurestudiesthat
seek to evaluate mechanistic hypotheses that may underlie
the observed comorbidity and its associations with hyper-
tensive disorders of pregnancy may yield new generalizable
knowledge that could potentially lead to improvements in
maternal and fetal outcomes.
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